BD to Present at Investor Healthcare Conferences

Fri Dec 21, 2012 3:00pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121221:nPnNY34062


FRANKLIN LAKES, N.J.,  Dec. 21, 2012  /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company, announced
today that it will present at the following investor healthcare conferences in 
January 2013:

Goldman Sachs Healthcare CEOs Unscripted:  A View From The Top
January 3, 2013
1:00 p.m. ET

31st  Annual J. P. Morgan Healthcare Conference
January 9, 2013
11:30 a.m. ET

Live webcasts of BD's presentations can be accessed on the BD corporate website
at  www.bd.com/investors.  They will be available for replay for a period of
seven days after each conference.  

About BD

BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents.  The Company is
dedicated to improving people's health throughout the world.  BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines.  BD's capabilities are instrumental in
combating many of the world's most pressing diseases.  Founded in 1897 and
headquartered in  Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world.  The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public.  For more information, please
visit  www.bd.com.

Contact:

Monique N. Dolecki, Investor Relations - 201-847-5378

Colleen T. White, Corporate Communications - 201-847-5369

 

SOURCE  BD (Becton, Dickinson and Company)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.